IL241250A0 - Macrocyclic inhibitors of rip2 kinase - Google Patents
Macrocyclic inhibitors of rip2 kinaseInfo
- Publication number
- IL241250A0 IL241250A0 IL241250A IL24125015A IL241250A0 IL 241250 A0 IL241250 A0 IL 241250A0 IL 241250 A IL241250 A IL 241250A IL 24125015 A IL24125015 A IL 24125015A IL 241250 A0 IL241250 A0 IL 241250A0
- Authority
- IL
- Israel
- Prior art keywords
- kinase inhibitors
- rip2 kinase
- macrocyclic
- macrocyclic rip2
- inhibitors
- Prior art date
Links
- 229940043355 kinase inhibitor Drugs 0.000 title 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 title 1
- 101150021296 rip2 gene Proteins 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/16—Peri-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/18—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/16—Peri-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/18—Bridged systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Diabetes (AREA)
- Pulmonology (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Obesity (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pain & Pain Management (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Ophthalmology & Optometry (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1304714.7A GB201304714D0 (en) | 2013-03-15 | 2013-03-15 | Macrocyclic RIP2 Kinase inhibitors |
| EP2013066732 | 2013-03-15 | ||
| PCT/EP2014/055139 WO2014140299A1 (en) | 2013-03-15 | 2014-03-14 | Macrocyclic rip2 kinase inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL241250A0 true IL241250A0 (en) | 2015-11-30 |
Family
ID=50342296
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL241250A IL241250A0 (en) | 2013-03-15 | 2015-09-07 | Macrocyclic inhibitors of rip2 kinase |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20160024114A1 (enExample) |
| JP (1) | JP2016510796A (enExample) |
| KR (1) | KR20150133765A (enExample) |
| CN (1) | CN105228625A (enExample) |
| AU (1) | AU2014230111A1 (enExample) |
| BR (1) | BR112015022982A2 (enExample) |
| CA (1) | CA2906257A1 (enExample) |
| EA (1) | EA201591773A1 (enExample) |
| HK (1) | HK1218263A1 (enExample) |
| IL (1) | IL241250A0 (enExample) |
| MX (1) | MX2015012526A (enExample) |
| SG (1) | SG11201507594YA (enExample) |
| WO (1) | WO2014140299A1 (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016146651A1 (en) * | 2015-03-16 | 2016-09-22 | Oncodesign Sa | Macrocyclic activin-like receptor kinase inhibitors |
| US11166967B2 (en) | 2016-05-19 | 2021-11-09 | Universiteit Antwerpen | Bis(acetamidophenyl) guanidinophenylethylphosphonates for use in the prevention and/or treatment of PAR-related diseases |
| AU2017302019A1 (en) * | 2016-07-28 | 2019-02-07 | Turning Point Therapeutics, Inc. | Macrocycle kinase inhibitors |
| KR102719387B1 (ko) * | 2017-01-26 | 2024-10-21 | 한미약품 주식회사 | 이미다조피리다진 화합물 |
| CN110386944B (zh) * | 2018-04-16 | 2021-10-29 | 深圳市塔吉瑞生物医药有限公司 | 用于抑制蛋白激酶活性的二(杂)芳基大环化合物 |
| RS66346B1 (sr) | 2018-10-22 | 2025-01-31 | Alumis Inc | Inhibitori tyk2 i njihova upotreba |
| CA3168814A1 (en) * | 2020-01-31 | 2021-08-05 | Oncodesign S.A. | Macrocyclic rip2-kinase inhibitors |
| IL301385A (en) | 2020-09-16 | 2023-05-01 | Alumis Inc | TYK2 inhibitors and their use |
| AU2023339247A1 (en) * | 2022-09-07 | 2025-03-27 | Suzhou Langrui Biopharmaceutical Co., Ltd. | Macrocyclic imidazo[1,2-b]pyridazine derivative, preparation method therefor, and use thereof |
| WO2025212514A2 (en) * | 2024-04-02 | 2025-10-09 | Interline Therapeutics, Inc. | Methods of treating inflammatory diseases |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AUPQ120999A0 (en) * | 1999-06-25 | 1999-07-22 | Industrial Automation Services Pty Ltd | Vibration suppressing piston |
| JP2004089182A (ja) * | 2002-06-24 | 2004-03-25 | Takeda Chem Ind Ltd | がんの予防・治療剤 |
| TWI547494B (zh) * | 2011-08-18 | 2016-09-01 | 葛蘭素史克智慧財產發展有限公司 | 作為激酶抑制劑之胺基喹唑啉類 |
| MX347765B (es) * | 2011-09-30 | 2017-05-12 | Oncodesign Sa | Inhibidores macrociclicos de la quinasa flt3. |
| PT2760453T (pt) * | 2011-09-30 | 2016-08-02 | Ipsen Pharma Sas | Inibidores macrocíclicos da cinase lrrk2 |
| CA2906262A1 (en) * | 2013-03-15 | 2014-09-18 | Oncodesign S.A. | Macrocyclic salt-inducible kinase inhibitors |
| PL2970333T3 (pl) * | 2013-03-15 | 2017-12-29 | Oncodesign S.A. | Makrocykliczne inhibitory kinazy LRRK2 |
-
2014
- 2014-03-14 WO PCT/EP2014/055139 patent/WO2014140299A1/en not_active Ceased
- 2014-03-14 JP JP2015562211A patent/JP2016510796A/ja not_active Withdrawn
- 2014-03-14 SG SG11201507594YA patent/SG11201507594YA/en unknown
- 2014-03-14 MX MX2015012526A patent/MX2015012526A/es unknown
- 2014-03-14 CN CN201480023821.5A patent/CN105228625A/zh active Pending
- 2014-03-14 EA EA201591773A patent/EA201591773A1/ru unknown
- 2014-03-14 BR BR112015022982A patent/BR112015022982A2/pt not_active IP Right Cessation
- 2014-03-14 US US14/776,889 patent/US20160024114A1/en not_active Abandoned
- 2014-03-14 AU AU2014230111A patent/AU2014230111A1/en not_active Abandoned
- 2014-03-14 KR KR1020157029469A patent/KR20150133765A/ko not_active Withdrawn
- 2014-03-14 HK HK16106342.4A patent/HK1218263A1/zh unknown
- 2014-03-14 CA CA2906257A patent/CA2906257A1/en not_active Abandoned
-
2015
- 2015-09-07 IL IL241250A patent/IL241250A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2014230111A1 (en) | 2015-10-29 |
| CA2906257A1 (en) | 2014-09-18 |
| CN105228625A (zh) | 2016-01-06 |
| EA201591773A1 (ru) | 2016-01-29 |
| JP2016510796A (ja) | 2016-04-11 |
| BR112015022982A2 (pt) | 2017-07-18 |
| KR20150133765A (ko) | 2015-11-30 |
| MX2015012526A (es) | 2016-04-26 |
| US20160024114A1 (en) | 2016-01-28 |
| SG11201507594YA (en) | 2015-10-29 |
| WO2014140299A1 (en) | 2014-09-18 |
| HK1218263A1 (zh) | 2017-02-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA201603337B (en) | Pyrimidopyrimidinones useful as wee-1 kinase inhibitors | |
| IL243371A0 (en) | bromine zone inhibitors | |
| IL241123A0 (en) | Dihydro-pyrrolopyridinones as inhibitors of bromo sites | |
| SG11201508125XA (en) | Protein kinase inhibitors | |
| HUE048371T2 (hu) | Bromodomén inhibitorok | |
| EP3016953A4 (en) | Purinone compounds as kinase inhibitors | |
| ZA201506327B (en) | Macrocyclic lrrk2 kinase inhibitors | |
| SG11201507594YA (en) | Macrocyclic rip2 kinase inhibitors | |
| IL241325A0 (en) | Salt-induced macrocyclic kinase inhibitors | |
| ZA201604461B (en) | Serine/threonine kinase inhibitors | |
| IL244029B (en) | Deoxycytodine kinase inhibitors | |
| ZA201701331B (en) | Macrocyclic rip2 kinase inhibitors | |
| EP3074401A4 (en) | Protein kinase inhibitors | |
| GB201307155D0 (en) | Kinase inhibitors | |
| GB201304714D0 (en) | Macrocyclic RIP2 Kinase inhibitors | |
| GB201300087D0 (en) | Dram | |
| GB201323021D0 (en) | Use of kinase inhibitors | |
| GB201321227D0 (en) | Use of kinase inhibitors | |
| HK1224675A1 (en) | Purinone compounds as kinase inhibitors | |
| GB201309603D0 (en) | Novel compounds and their use as kinase inhibitors | |
| GB201305741D0 (en) | Novel compounds and their use as kinase inhibitors |